Palogic Value Management’s Rein Therapeutics RNTX Stock Holding History

Palogic Value Management’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$234K	Buy	+180,000	New	+$223K	0.1%	165

Other funds holding RNTX

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Palogic Value Management's RNTX Position: Q1 2026 in Review

Palogic Value Management opened a new position in Rein Therapeutics (RNTX) in Q1 2026: 180,000 shares worth $234K. The stake represents 0.1% of the portfolio and ranks #165 among its holdings.

46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

Palogic Value Management held 180,000 shares of Rein Therapeutics worth $234K as of Q1 2026.
Rein Therapeutics was a new Palogic Value Management position in Q1 2026.
Rein Therapeutics made up 0.1% of Palogic Value Management's portfolio in Q1 2026, its #165 holding.
46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on Palogic Value Management's 13F filing for Q1 2026, filed 15 May 2026.